Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide vs Enzalutamide Effects on Cerebral Blood Flow
NCT03704519Phase 1Completed
- Sponsor
- Bayer
- Start
- Oct 2018
- Primary completion
- Oct 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of darolutamide in prostate cancer (PCa) (6 arms), sponsored by Bayer. Primary endpoint: Change in grey-matter cerebral blood flow at 4 hours. Started Oct 2018; status: completed.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03704519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03704519.